The current status of clinical research on immune checkpoint inhibitors rechallenge in non-small cell lung cancer
10.3781/j.issn.1000-7431.2024.2402-0078
- VernacularTitle:非小细胞肺癌免疫检查点抑制剂再挑战治疗的临床研究现状
- Author:
Chenyang ZHANG
1
;
Meiling XU
1
;
Rongzheng CHEN
1
;
Pengfei XING
1
;
Yuehong KONG
1
;
Xiangrong ZHAO
1
;
Junjun ZHANG
1
;
Liyuan ZHANG
1
Author Information
1. 苏州大学附属第二医院布拉格治疗中心,江苏 苏州 215104;苏州大学附属第二医院肿瘤诊疗中心,江苏 苏州 215104;苏州大学附属第二医院肿瘤放射免疫治疗实验室,江苏 苏州 215104
- Publication Type:Journal Article
- Keywords:
Non-small cell lung cancer;
Immune checkpoint inhibitors;
Rechallenge
- From:
Tumor
2024;44(4):404-411
- CountryChina
- Language:Chinese
-
Abstract:
The application of immune checkpoint inhibitors has changed the treatment paradigm for advanced non-small cell lung cancer(NSCLC).However,interruption of immune checkpoint inhibitor therapy due to intolerable adverse effects or due to disease progression has become a problematic issue in the treatment of advanced NSCLC.Whether immune checkpoint inhibitors rechallenge therapy is possible after interruption of immune checkpoint inhibitor therapy has been proposed and remains controversial.This article summarizes the types of immune checkpoint inhibitor rechallenge and therapeutic strategies for advanced NSCLC,and finds that patients with NSCLC who have interrupted their immunotherapy due to immune-related adverse events and clinical decision-making can still achieve a better favorable clinical outcomes.It is hypothesized that immune checkpoint inhibitor rechallenge for NSCLC after drug resistance is an alternative salvage therapy.
